Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 3

5938 - Cambridge Liquid biopsy “CALIBRATION” study: Can changes in circulating tumour DNA (ctDNA) predict durable tumour responses in patients with advanced oesophageal cancer receiving MEDI4736?


30 Sep 2019


Poster Display session 3


Translational Research

Tumour Site


Constanza Linossi


Annals of Oncology (2019) 30 (suppl_5): v25-v54. 10.1093/annonc/mdz239


C. Linossi1, A. Williams2, R. Baird3, S. Dovedi4, R. Fitzgerald5, S. Pacey6

Author affiliations

  • 1 The Hutchinson/mrc Research Centre, University of Cambridge, CB2 0XZ - Cambridge/GB
  • 2 Cambridge Clinical Trials Unit, Cambridge Cancer Trials Centre, CB2 0QQ - Cambridge/GB
  • 3 Department Of Oncology, Cambridge University, CB2 0QQ - Cambridge/GB
  • 4 Oncology, AstraZeneca, CB21 6GP - Cambridge/GB
  • 5 Mrc Cancer Unit, University of Cambridge, CB2 0XZ - Cambridge/GB
  • 6 Department Of Oncology, University of Cambridge, CB2 0QQ - Cambridge/GB


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 5938


Oesophageal cancer is the 6th most common cause of cancer death with incidence of adenocarcinomas (EAC) increasing in western countries. Long term survival is poor (<5%) (ESMO guidelines 2016) and mutational signatures of EAC suggest patients with "mutagenic" or "DDR" signatures can benefit from immune-checkpoint blockers (ICB) (Secriert et al. Nat gen 2016). However, there is uncertainty around the population to benefit from ICBs. Circulating tumour DNA (ctDNA) can be used to predict responses to immuno-oncology (IO) agents (Howell J, Trans res 2017). TP53 mutations is frequent in EAC 6 and ctDNA-TP53 mutations can be measured/followed in plasma to track tumour behaviour (response, clonal changes) during treatment (Zill O. Clin Can Res 2018, Fisher O. Gut 2017). Next-generation sequencing (NGS) provides high sensitivity, coverage and the possibility to interrogate tumour treatment-response and heterogeneity.

Trial design

CALIBRATION is a single-centre, open-label, pilot trial of durvalumab (1500mg/4w) for patients with EAC progressing to standard chemotherapy. Pts with measurable disease undergo biopsies at screening/C3/progression alongside weekly blood sampling. Primary objective: asses if early changes in TP53 ctDNA variant allele fraction (VAF) levels, by weeks 4 and/ or 7 can predict durable (6 month) RECIST V 1.1 responses (Complete or Partial Response, Stable Disease). We plan to recruit 19 pts with a 5 % significance (one-sided) and 80 % power to detect if ctDNA changes correctly predict radiological response in ≥ 70 % pts. The trial opened to recruitment in October 2018, 13 pts have been pre-screened and 4 pts included. An interim analysis is planned for September 2019. Secondary endpoints include characterization of paired blood/biopsy samples from pts pre/post durvalumab of: • genomic heterogeneity (evolution of mutational signatures under IO) and changes in the tumour microenvironment (dynamics of T-cell populations). • changes in ctDNA and PBMC markers to identify biomarkers of resistance/response. • predictive value of the mutagenic and DDR signatures to predict response to IO compounds.

Clinical trial identification


Editorial acknowledgement

Legal entity responsible for the study

Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge.




S. Dovedi: Leadership role: AstraZeneca.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.